HCV NS5A replication complex inhibitors. Part 3 : discovery of potent analogs with distinct core topologies
Omar D. Lopez(Bristol-Myers Squibb (United States)), Lawrence B. Snyder(Arvinas (United States)), Makonen Belema, Jason T. Goodrich(Bristol-Myers Squibb (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Donald R. O’Boyle(Bristol-Myers Squibb (United States)), Lourdes Valera(Bristol-Myers Squibb (United States)), Denis R. St. Laurent(Bristol-Myers Squibb (United States)), Peter T. Nower, Amy S. Ripka(Bristol-Myers Squibb (United States)), Robert A. Fridell(Bristol-Myers Squibb (United States)), Yuping Qiu(Southwest Forestry University), Jin-Hua Sun(University of Science and Technology of China), Michael H. Serrano‐Wu(Broad Institute), Min Gao(Peking University), Fukang Yang(Bristol-Myers Squibb (United States)), Andrew C. Good(Bristol-Myers Squibb (United States)), Julie A. Lemm(Bristol-Myers Squibb (United States)), Van N. Nguyen, Mengping Liu(China University of Geosciences (Beijing))
Cited by 29
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Applications of fluorine-containing amino acids for drug design
|European Journal of Medicinal Chemistry|2019|238
Identification of Hepatitis C Virus NS5A Inhibitors
|Journal of Virology|2009|196
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186